Axillary Dissection — The Bell Tolls for Thee

The reliance on axillary-lymph-node dissection in the management of breast cancer has evolved over time. Although axillary-lymph-node dissection was long considered to be the standard of care for axillary staging, sentinel-node biopsy emerged in the mid-1990s as an alternative to axillary-lymph-node...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 390; no. 13; pp. 1231 - 1232
Main Author McGuire, Kandace P.
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.04.2024
Subjects
Biopsy
Breast Cancer
Breast surgery
Clinical trials
Dissection
Hematology
Lumpectomy
Lymph
Mastectomy
Oncology
Patients
Radiation therapy
Standard of care
Surgery
Surgery General
Treatments in Oncology
Womens health
Online AccessGet full text

Cover

More Information
Summary:The reliance on axillary-lymph-node dissection in the management of breast cancer has evolved over time. Although axillary-lymph-node dissection was long considered to be the standard of care for axillary staging, sentinel-node biopsy emerged in the mid-1990s as an alternative to axillary-lymph-node dissection for patients with clinically node-negative breast cancer. Over the next decade, at least two randomized trials supported sentinel-node biopsy as the standard for axillary staging in patients with node-negative disease, 1,2 and this approach was eventually adopted worldwide. However, axillary-lymph-node dissection remained the standard of care for patients who had positive results on sentinel-node biopsy for the purposes of . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe2401805